查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
替代血液替代品市场 - 全球和区域分析：按应用、按最终用途、按产品、按来源、按类型、按成分、按地区 - 分析和预测（2024-2034）
市场调查报告书
商品编码
1545608

替代血液替代品市场 - 全球和区域分析：按应用、按最终用途、按产品、按来源、按类型、按成分、按地区 - 分析和预测（2024-2034）

Synthetic Blood Substitute Market - A Global and Regional Analysis: Focus on Application, End-use, Product, Source, Type, Configuration, and Region - Analysis and Forecast, 2024-2034
出版日期: | 出版商: BIS Research | 英文 105 Pages | 商品交期: 1-5个工作天内

价格
简介目录

人工血液替代的市场规模正快速崛起，作为解决传统输血限制的重要解决方案，广泛应用于全球各个医疗领域。

随着创伤、手术和慢性疾病的增加，合成血液替代提供了可靠且安全的替代方案，确保重要血液成分的不间断供应。在乐观的情况下，2024 年市场价值为 870 万美元，预计将以 15.43% 的复合年增长率增长，到 2034 年达到 3,670 万美元。

医疗进步和对可靠血液替代品日益增长的需求正在推动医疗保健领域对替代血液替代品的需求。随着创伤、手术和慢性病的发生率持续上升，人们越来越需要有效、安全的血液替代来克服传统输血的限制。人造血液替代能够模仿天然血液的携氧和凝血功能，正成为急诊医学、外科和慢性病管理等应用的重要解决方案。

主要市场统计数据
预测期 2024-2034
2024年评估 870万美元
2034 年预测 3670万美元
复合年增长率 15.43%

替代血液替代品市场面临研发成本高、监管核准复杂等挑战。此外，确保这些血液替代在不同疾病状态下的安全性和有效性为市场进入和扩张带来了额外的复杂性。然而，这些挑战正在推动生物技术公司、医疗保健提供者和监管机构之间的创新和合作，以加速更先进的合成血液替代的开发，并扩大其在现代医学中的潜在应用。

以美国为首的北美，在其先进的生物医学研究部门和发达的医疗基础设施的推动下，主导着人工血液替代市场。由于研发方面的大力投入和监管机构的大力支持，美国在合成血液替代的开发方面处于领先地位。这种环境促进创新并生产尖端的合成血液产品，满足创伤治疗、手术和慢性病管理的关键需求。此外，随着美国努力改善医疗保健结果并解决血液供不应求，人造血液替代越来越多地在各个医疗领域被采用。随着对病人安全和技术进步的关注，美国人工血液替代的有效性和可靠性不断提高。美国专注于加强医疗保健和满足日益增长的血液替代需求，巩固了其在全球人造血液市场领先国家的地位。

该报告调查了全球替代血液替代品市场，并提供了市场概况、应用趋势、最终用途、产品、原产地、类型、成分、地区和进入市场的公司等。

目录

执行摘要

第一章市场：产业展望

  • 趋势：当前和未来的影响评估
  • 供应链概览
  • 研发回顾
  • 监管状况
  • 相关利益者分析
  • 全球重大事件影响分析
  • 市场动态概览

第二章 人工血液替代市场（依用途）

  • 应用细分
  • 应用概述
  • 人工血液替代市场（依应用）
  • 人造血液替代市场（依最终用途）

第三章 人工血液替代市场（依产品）

  • 产品细分
  • 产品概述
  • 人工血液替代市场（分产品）
  • 人工血液替代市场（依产地划分）
  • 人工血液替代市场（按类型）
  • 人工血液替代市场（依成分）

第四章 人工血液替代市场（分地区）

  • 人工血液替代市场（按地区）
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他领域

第五章 公司简介

  • 未来展望
  • 地理评估
  • 公司简介
    • Aurum Biosciences
    • HEMARINA
    • Hemoglobin Oxygen Therapeutics LLC
    • KaloCyte, Inc.
    • Spheritech Ltd
    • VisusMed Medical Center
    • OPKO Health, Inc.
    • NuvOx Pharma
    • Prolong Pharmaceuticals
    • Boston Pharmaceuticals
    • ATPL
    • Baxter
    • Biopharma corp
    • NORTHFIELD LABORATORIES INC.
    • Alliance Pharma PLC
    • 其他主要企业

第六章调查方法

简介目录
Product Code: BHL2234SA

Introduction to Synthetic Blood Substitute Market

The synthetic blood substitute market is rapidly emerging as a critical solution to address the limitations of traditional blood transfusions, finding widespread applications across various medical fields globally. With increasing incidences of trauma, surgeries, and chronic diseases, synthetic blood substitutes offer a reliable and safe alternative, ensuring an uninterrupted supply of vital blood components. In an optimistic scenario, the market, valued at $8.7 million in 2024, is anticipated to grow at a CAGR of 15.43%, reaching $36.7 million by 2034.

Increasing medical advancements and a growing need for reliable blood alternatives are driving the demand for synthetic blood substitutes in the healthcare sector. As incidences of trauma, surgeries, and chronic diseases continue to rise, there is a growing necessity for effective and safe blood substitutes that can overcome the limitations of traditional blood transfusions. Synthetic blood substitutes, with their ability to mimic the oxygen-carrying and clotting functions of natural blood, have emerged as a critical solution across applications such as emergency medicine, surgeries, and chronic disease management.

KEY MARKET STATISTICS
Forecast Period2024 - 2034
2024 Evaluation$8.7 Million
2034 Forecast$36.7 Million
CAGR15.43%

In the synthetic blood substitute market, challenges include high research and development costs and the complexities associated with regulatory approvals. Additionally, ensuring the safety and efficacy of these substitutes in diverse medical conditions adds further complexity to market entry and expansion. However, these challenges promotes innovation and collaboration among biotech firms, healthcare providers, and regulatory bodies, driving the development of more advanced synthetic blood substitutes and expanding their potential applications in modern medicine.

North America, led by the U.S., dominates the synthetic blood substitute market, driven by its advanced biomedical research sector and substantial healthcare infrastructure. U.S. leads in synthetic blood substitute development due to its robust investment in research and development, coupled with strong support from regulatory bodies. This environment promotes innovation, resulting in cutting-edge synthetic blood products that address critical needs in trauma care, surgeries, and chronic disease management. Furthermore, the U.S. commitment to improving healthcare outcomes and addressing blood supply shortages propels the adoption of synthetic blood substitutes across various medical fields. The nation's emphasis on patient safety and technological advancements ensures that synthetic blood substitutes are continually refined for efficacy and reliability. With a focus on enhancing medical care and meeting the increasing demand for blood substitutes, the U.S. solidifies its position as a key player in the global synthetic blood substitute market.

Key players such as Aurum Biosciences, HEMARINA, Hemoglobin Oxygen Therapeutics LLC, and KaloCyte, Inc. are at the forefront of market expansion, utilizing their technological expertise and strategic partnerships to drive innovation and capture a significant market share. Companies are investing in the construction of new production facilities and the expansion of existing ones to meet the growing demand. For instance, in September 2022, VirTech Bio received approximately $13.7 million in funding from the Pentagon and the U.S. Department of Defense (DoD) to advance the clinical research of its hemoglobin-based oxygen-carrying solution, OxyBridge. This product is designed to prevent hemorrhagic shock in trauma patients and enhance the viability of organs donated for transplantation.

Market Segmentation:

Segmentation 1: by Application

  • Cardiovascular Diseases
  • Malignant Neoplasma
  • Injuries
  • Neonatal Conditions
  • Organ Transplant
  • Maternal Condition
  • Others

Segmentation 2: by End-use

  • Hospitals
  • Ambulatory Surgical Centers
  • Military and Defense
  • Research Laboratories
  • Emergency Services
  • Others

Segmentation 3: by Product

  • Hemoglobin-Based Oxygen Carriers (HBOCs)
  • Perfluorocarbon Emulsions (PFCs)
  • Stem Cell-Derived Red Blood Cells
  • Others

Segmentation 4: by Source

  • Human Blood
  • Microorganism Based Recombinant HB
  • Synthetic Polymers
  • Stem Cells
  • Others

Segmentation 5: by Component

  • Red Blood Cell Substitutes
  • Platelet Substitutes
  • Plasma Substitutes

Segmentation 6: by Configuration

  • Injectable Solutions
  • Powdered Forms
  • Infusion Bags
  • Capsules and Tablets
  • Others

Segmentation 7: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

How can this report add value to an organization?

Product/Innovation Strategy: The global synthetic blood substitute market has been extensively segmented based on various categories, such as application, end-use, product, source, component, and configuration. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: A detailed competitive benchmarking of the players operating in the global synthetic blood substitute market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some of the prominent companies in this market are:

  • Aurum Biosciences
  • HEMARINA
  • Hemoglobin Oxygen Therapeutics LLC
  • KaloCyte, Inc.
  • Spheritech Ltd
  • NuvOx Pharma
  • Prolong Pharmaceuticals
  • Boston Pharmaceuticals

Key Questions Answered in this Report:

  • What are the main factors driving the demand for synthetic blood substitute market?
  • What are the major patents filed by the companies active in synthetic blood substitute market?
  • Who are the key players in the synthetic blood substitute market, and what are their respective market shares?
  • What are the strategies adopted by the key companies to gain a competitive edge in synthetic blood substitute market?
  • What is the futuristic outlook for the synthetic blood substitute market in terms of growth potential?
  • What is the current estimation of the synthetic blood substitute market, and what growth trajectory is projected from 2024 to 2034?
  • Which application, and product segment is expected to lead the market over the forecast period (2024-2034)?
  • Which regions demonstrate the highest adoption rates for synthetic blood substitute market, and what factors contribute to their leadership?

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Increasing Demand for Blood Transfusions due to Rising Trauma and Chronic Diseases
    • 1.1.2 Advancement in Stem Cell Technology and Regenerative Medicine
    • 1.1.3 Integration with Advanced Diagnostics and Monitoring
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
    • 1.2.2 Pricing Forecast
  • 1.3 R&D Review
    • 1.3.1 Patent Filing Trend by Country, by Company
  • 1.4 Regulatory Landscape
  • 1.5 Stakeholder Analysis
    • 1.5.1 Use Case
    • 1.5.2 End User and Buying Criteria
  • 1.6 Impact Analysis for Key Global Events
  • 1.7 Market Dynamics Overview
    • 1.7.1 Market Drivers
    • 1.7.2 Market Restraints
    • 1.7.3 Market Opportunities

2. Synthetic Blood Substitute Market (by Application)

  • 2.1 Application Segmentation
  • 2.2 Application Summary
  • 2.3 Synthetic Blood Substitute Market (by Application)
    • 2.3.1 Cardiovascular Diseases
    • 2.3.2 Malignant Neoplasma
    • 2.3.3 Injuries
    • 2.3.4 Neonatal Conditions
    • 2.3.5 Organ Transplant
    • 2.3.6 Maternal Condition
    • 2.3.7 Others
  • 2.4 Synthetic Blood Substitute Market (by End-use)
    • 2.4.1 Hospitals
    • 2.4.2 Ambulatory Surgical Centers
    • 2.4.3 Military and Defense
    • 2.4.4 Research Laboratories
    • 2.4.5 Emergency Services
    • 2.4.6 Others

3. Synthetic Blood Substitute Market (by Product)

  • 3.1 Product Segmentation
  • 3.2 Product Summary
  • 3.3 Synthetic Blood Substitute Market (by Product)
    • 3.3.1 Hemoglobin-Based Oxygen Carriers (HBOCs)
    • 3.3.2 Perfluorocarbon Emulsions (PFCs)
    • 3.3.3 Stem Cell-Derived Red Blood Cells
    • 3.3.4 Others
  • 3.4 Synthetic Blood Substitute Market (by Source)
    • 3.4.1 Human Blood
    • 3.4.2 Microorganism Based Recombinant HB
    • 3.4.3 Synthetic Polymers
    • 3.4.4 Stem Cells
    • 3.4.5 Others
  • 3.5 Synthetic Blood Substitute Market (by Type)
    • 3.5.1 Red Blood Cell Substitutes
    • 3.5.2 Platelet Substitutes
    • 3.5.3 Plasma Substitutes
  • 3.6 Synthetic Blood Substitute Market (by Configuration)
    • 3.6.1 Injectable Solutions
    • 3.6.2 Powdered Forms
    • 3.6.3 Infusion Bags
    • 3.6.4 Capsules and Tablets
    • 3.6.5 Others

4. Synthetic Blood Substitute Market (by Region)

  • 4.1 Synthetic Blood Substitute Market (by Region)
  • 4.2 North America
    • 4.2.1 Regional Overview
    • 4.2.2 Driving Factors for Market Growth
    • 4.2.3 Factors Challenging the Market
    • 4.2.4 Application
    • 4.2.5 Product
    • 4.2.6 North America Synthetic Blood Substitute Market (by Country)
      • 4.2.6.1 U.S.
        • 4.2.6.1.1 Market by Application
        • 4.2.6.1.2 Market by Product
      • 4.2.6.2 Canada
        • 4.2.6.2.1 Market by Application
        • 4.2.6.2.2 Market by Product
      • 4.2.6.3 Mexico
        • 4.2.6.3.1 Market by Application
        • 4.2.6.3.2 Market by Product
  • 4.3 Europe
    • 4.3.1 Regional Overview
    • 4.3.2 Driving Factors for Market Growth
    • 4.3.3 Factors Challenging the Market
    • 4.3.4 Application
    • 4.3.5 Product
    • 4.3.6 Europe Synthetic Blood Substitute Market (by Country)
      • 4.3.6.1 Germany
        • 4.3.6.1.1 Market by Application
        • 4.3.6.1.2 Market by Product
      • 4.3.6.2 France
        • 4.3.6.2.1 Market by Application
        • 4.3.6.2.2 Market by Product
      • 4.3.6.3 U.K.
        • 4.3.6.3.1 Market by Application
        • 4.3.6.3.2 Market by Product
      • 4.3.6.4 Italy
        • 4.3.6.4.1 Market by Application
        • 4.3.6.4.2 Market by Product
      • 4.3.6.5 Rest-of-Europe
        • 4.3.6.5.1 Market by Application
        • 4.3.6.5.2 Market by Product
  • 4.4 Asia-Pacific
    • 4.4.1 Regional Overview
    • 4.4.2 Driving Factors for Market Growth
    • 4.4.3 Factors Challenging the Market
    • 4.4.4 Application
    • 4.4.5 Product
    • 4.4.6 Asia-Pacific Synthetic Blood Substitute Market (by Country)
      • 4.4.6.1 China
        • 4.4.6.1.1 Market by Application
        • 4.4.6.1.2 Market by Product
      • 4.4.6.2 Japan
        • 4.4.6.2.1 Market by Application
        • 4.4.6.2.2 Market by Product
      • 4.4.6.3 India
        • 4.4.6.3.1 Market by Application
        • 4.4.6.3.2 Market by Product
      • 4.4.6.4 South Korea
        • 4.4.6.4.1 Market by Application
        • 4.4.6.4.2 Market by Product
      • 4.4.6.5 Rest-of-Asia-Pacific
        • 4.4.6.5.1 Market by Application
        • 4.4.6.5.2 Market by Product
  • 4.5 Rest-of-the-World
    • 4.5.1 Regional Overview
    • 4.5.2 Driving Factors for Market Growth
    • 4.5.3 Factors Challenging the Market
    • 4.5.4 Application
    • 4.5.5 Product
    • 4.5.6 Rest-of-the-World Synthetic Blood Substitute Market (by Region)
      • 4.5.6.1 South America
        • 4.5.6.1.1 Market by Application
        • 4.5.6.1.2 Market by Product
      • 4.5.6.2 Middle East and Africa
        • 4.5.6.2.1 Market by Application
        • 4.5.6.2.2 Market by Product

5. Companies Profiled

  • 5.1 Next Frontiers
  • 5.2 Geographic Assessment
  • 5.3 Company Profiles
    • 5.3.1 Aurum Biosciences
      • 5.3.1.1 Overview
      • 5.3.1.2 Top Products/Product Portfolio
      • 5.3.1.3 Top Competitors
      • 5.3.1.4 Target Customers
      • 5.3.1.5 Key Personnel
      • 5.3.1.6 Analyst View
      • 5.3.1.7 Market Share
    • 5.3.2 HEMARINA
      • 5.3.2.1 Overview
      • 5.3.2.2 Top Products/Product Portfolio
      • 5.3.2.3 Top Competitors
      • 5.3.2.4 Target Customers
      • 5.3.2.5 Key Personnel
      • 5.3.2.6 Analyst View
      • 5.3.2.7 Market Share
    • 5.3.3 Hemoglobin Oxygen Therapeutics LLC
      • 5.3.3.1 Overview
      • 5.3.3.2 Top Products/Product Portfolio
      • 5.3.3.3 Top Competitors
      • 5.3.3.4 Target Customers
      • 5.3.3.5 Key Personnel
      • 5.3.3.6 Analyst View
      • 5.3.3.7 Market Share
    • 5.3.4 KaloCyte, Inc.
      • 5.3.4.1 Overview
      • 5.3.4.2 Top Products/Product Portfolio
      • 5.3.4.3 Top Competitors
      • 5.3.4.4 Target Customers
      • 5.3.4.5 Key Personnel
      • 5.3.4.6 Analyst View
      • 5.3.4.7 Market Share
    • 5.3.5 Spheritech Ltd
      • 5.3.5.1 Overview
      • 5.3.5.2 Top Products/Product Portfolio
      • 5.3.5.3 Top Competitors
      • 5.3.5.4 Target Customers
      • 5.3.5.5 Key Personnel
      • 5.3.5.6 Analyst View
      • 5.3.5.7 Market Share
    • 5.3.6 VisusMed Medical Center
      • 5.3.6.1 Overview
      • 5.3.6.2 Top Products/Product Portfolio
      • 5.3.6.3 Top Competitors
      • 5.3.6.4 Target Customers
      • 5.3.6.5 Key Personnel
      • 5.3.6.6 Analyst View
      • 5.3.6.7 Market Share
    • 5.3.7 OPKO Health, Inc.
      • 5.3.7.1 Overview
      • 5.3.7.2 Top Products/Product Portfolio
      • 5.3.7.3 Top Competitors
      • 5.3.7.4 Target Customers
      • 5.3.7.5 Key Personnel
      • 5.3.7.6 Analyst View
      • 5.3.7.7 Market Share
    • 5.3.8 NuvOx Pharma
      • 5.3.8.1 Overview
      • 5.3.8.2 Top Products/Product Portfolio
      • 5.3.8.3 Top Competitors
      • 5.3.8.4 Target Customers
      • 5.3.8.5 Key Personnel
      • 5.3.8.6 Analyst View
      • 5.3.8.7 Market Share
    • 5.3.9 Prolong Pharmaceuticals
      • 5.3.9.1 Overview
      • 5.3.9.2 Top Products/Product Portfolio
      • 5.3.9.3 Top Competitors
      • 5.3.9.4 Target Customers
      • 5.3.9.5 Key Personnel
      • 5.3.9.6 Analyst View
      • 5.3.9.7 Market Share
    • 5.3.10 Boston Pharmaceuticals
      • 5.3.10.1 Overview
      • 5.3.10.2 Top Products/Product Portfolio
      • 5.3.10.3 Top Competitors
      • 5.3.10.4 Target Customers
      • 5.3.10.5 Key Personnel
      • 5.3.10.6 Analyst View
      • 5.3.10.7 Market Share
    • 5.3.11 ATPL
      • 5.3.11.1 Overview
      • 5.3.11.2 Top Products/Product Portfolio
      • 5.3.11.3 Top Competitors
      • 5.3.11.4 Target Customers
      • 5.3.11.5 Key Personnel
      • 5.3.11.6 Analyst View
      • 5.3.11.7 Market Share
    • 5.3.12 Baxter
      • 5.3.12.1 Overview
      • 5.3.12.2 Top Products/Product Portfolio
      • 5.3.12.3 Top Competitors
      • 5.3.12.4 Target Customers
      • 5.3.12.5 Key Personnel
      • 5.3.12.6 Analyst View
      • 5.3.12.7 Market Share
    • 5.3.13 Biopharma corp
      • 5.3.13.1 Overview
      • 5.3.13.2 Top Products/Product Portfolio
      • 5.3.13.3 Top Competitors
      • 5.3.13.4 Target Customers
      • 5.3.13.5 Key Personnel
      • 5.3.13.6 Analyst View
      • 5.3.13.7 Market Share
    • 5.3.14 NORTHFIELD LABORATORIES INC.
      • 5.3.14.1 Overview
      • 5.3.14.2 Top Products/Product Portfolio
      • 5.3.14.3 Top Competitors
      • 5.3.14.4 Target Customers
      • 5.3.14.5 Key Personnel
      • 5.3.14.6 Analyst View
      • 5.3.14.7 Market Share
    • 5.3.15 Alliance Pharma PLC
      • 5.3.15.1 Overview
      • 5.3.15.2 Top Products/Product Portfolio
      • 5.3.15.3 Top Competitors
      • 5.3.15.4 Target Customers
      • 5.3.15.5 Key Personnel
      • 5.3.15.6 Analyst View
      • 5.3.15.7 Market Share
    • 5.3.16 Other Key Companies

6. Research Methodology